Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Vibegron Administered Orally for 12 Weeks to Women With Irritable Bowel Syndrome [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating oral vibegron for 12 weeks in women with irritable bowel syndrome has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• Vibegron (vibegron)

Snippet

Sponsor: Urovant Sciences GmbH | Conditions: Irritable Bowel Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2021-07-30